The recent renaming of Polycystic Ovary Syndrome (PCOS) to Polyendocrine Metabolic Ovary Syndrome (PMOS) marks a significant shift in women's health care. This change, which took 14 years to implement, aims to improve diagnosis and treatment by addressing the condition's complexity and its impact on various aspects of health. The new name, published in The Lancet, reflects the condition's endocrine and metabolic nature, moving away from a narrow focus on reproductive issues. This shift is crucial as it addresses the widespread delays in diagnosis and fragmented care experienced by women with PCOS, as highlighted by the PCOS All-Party Parliamentary Group (APPG) report. The new name, PMOS, is a more accurate representation of the condition's multifaceted nature, encompassing reproductive, metabolic, and mental health impacts. This change is expected to attract more funding and research, as well as improve the diagnostic experience for patients. The renaming process involved collaboration between experts and women with PMOS, ensuring a patient-centric approach. The new name aims to address cultural issues and stigma associated with the previous term, which often focused on fertility consequences rather than the broader health implications. Patients have expressed overwhelming relief and validation, feeling that their symptoms and experiences are finally being recognized and understood. However, the transition to PMOS will take time, requiring updates to guidelines, pathways, and coding. Despite this, the change is seen as a crucial step towards better care and a more comprehensive understanding of women's health issues. The renaming of PCOS to PMOS is a significant milestone, offering hope for improved diagnosis, treatment, and awareness of this complex hormonal condition.
